Work

Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from phase 1 dose escalation and NSCLC Expansion Cohort.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.e21057

Authors: Victor Moreno Garcia, Emiliano Calvo, Maria Eugenia Olmedo Garcia, Marta Gil Martin, Raid Aljumaily, Kyriakos P. Papadopoulos, Lee S. Rosen, Petra Rietschel, Kosalai Kal Mohan, Jingjin Li, Elizabeth Stankevich, Tracey Rowlands, Minjie Feng, Matthew G. Fury

Institutions: Hospital Universitario Ramón y Cajal, Institut Català d'Oncologia, University of Oklahoma Medical Center, South Texas Accelerated Research Therapeutics, University of California, Los Angeles, Regeneron (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890485958

Cites:

Cited by: 5

Related to: 10